Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes

2021739 citationsJournal Articlebronze Open Access

Authors

Hertzel C. Gerstein · Population Health Research Institute

Naveed Sattar · Population Health Research Institute

Julio Rosenstock · Population Health Research Institute

Chinthanie Ramasundarahettige · Population Health Research Institute

Richard E. Pratley · Population Health Research Institute

Renato D. Lópes · Population Health Research Institute

Carolyn S.P. Lam

Abstract

In this trial involving participants with type 2 diabetes who had either a history of cardiovascular disease or current kidney disease plus at least one other cardiovascular risk factor, the risk of cardiovascular events was lower among those who received weekly subcutaneous injections of efpeglenatide at a dose of 4 or 6 mg than among those who received placebo. (Funded by Sanofi; AMPLITUDE-O ClinicalTrials.gov number, NCT03496298.).

Topics & Keywords

Diabetes Treatment and Management Heart Failure Treatment and Management Diabetes Management and Research

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 385, Issue 10, pp. 896-907

DOI: 10.1056/nejmoa2108269

Field-Weighted Citation Impact: 74.94